Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 53-61 , 15 April 2010

Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C

  • Robin C. Hilsabeck

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States
    • Corresponding Author InformationCorresponding author. South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States. Tel.: +1 210 617 5121 (office); fax: +1 210 949 3301.
    • ,
  • Gregory M. Anstead

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States
    • ,
  • Amy L. Webb

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States
    • ,
  • Anastasio Hoyumpa

      Affiliations

    • Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States
    • ,
  • Paul Ingmundson

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • ,
  • Steve Holliday

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States
    • ,
  • Qiong Zhang

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • ,
  • Angela M. Casas

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • ,
  • Marci Jovel

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • ,
  • Stephen L. Stern

      Affiliations

    • South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX 78229, United States
    • Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, United States

Received 12 October 2009 ,Revised 13 January 2010 ,Accepted 29 January 2010.

References 

  1. Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell HC, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immun. 1998;161:5016–5026
  2. Anisman H, Poulter MO, Gandhi R, Merali Z, Hayley SL. Interferon-α effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone, and brain monoamine variations. J. Neuroimmunol. 2007;186:45–53
  3. Batteux F, Palmer P, Daëron M, Weill B, Lebon P. FCγRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur. Cytokine Network. 1999;10:509–514
  4. Baune BT, Ponath G, Golledge J, Varga G, Arolt V, Rothermundt M, et al. Association between IL-8 cytokine and cognitive performance in an elderly general population—the MEMO-Study. Neurobiol. Aging. 2008;29:937–944
  5. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 2008;117:198–202
  6. Bower WA, Culver DH, Castor D, Wu Y, James VN, Zheng H, et al. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. JAIDS. 2006;42:293–297
  7. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology. 1996;24:6–9
  8. Calvert M, Gresser I. Interferon enhances the excitability of cultured neurons. Nature. 1979;278:558–560
  9. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α. Brain Res. 1999;835:46–61
  10. Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Nemeroff CB, Berns GS, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol. Psychiatry. 2005;58:190–196
  11. Castellano-Higuera A, Gonzalez-Reimers E, Aleman-Valls MR, Abreu-Gonzalez P, Santolaria-Fernandez F, De La Vega-Prieto MJ, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol. 2008;43:137–142
  12. Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res.: J. Lab. Clin. Med. 2007;150:116–121
  13. Chen J, Buchanan JB, Sparkman NL, Godbout JP, Freund GG, Johnson RW. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun. 2008;22:301–311
  14. Cribier B, Schmitt C, Rey D, Lang JM, Kirn A, Stoll-Keller F. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res. Virol. 1996;147:263–266
  15. Crow YJ, Jackson AP, Roberts E, van Beusekom E, Barth P, Corry P, et al. Aicardi–Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am. J. Hum. Genet. 2000;67:213–221
  16. Crow YJ, Black DN, Ali M, Bond J, Jackson AP, Lefson M, et al. Cree encephalitis is allelic with Aicardi–Goutières syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J. Med. Genetics. 2003;40:183–187
  17. Dafny N, Prieto-Gomez B, Dong WQ, Reyes-Vazquez C. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res. 1996;734:269–274
  18. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry. 2000;157:867–876
  19. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005;64:1371–1377
  20. Dinarello CA, Bernheim HA, Duff GW, Le HV, Nagabhushan TL, Hamilton NC, et al. Mechanisms of fever induced by recombinant human interferon. J. Clin. Invest. 1984;74:906–913
  21. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 2006;36:144–150
  22. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet. 1985;1:1166
  23. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J. Hepatol. 2005;43:614–622
  24. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358:38–39
  25. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439
  26. Goutières F, Aicardi J, Barth PG, Lebon P. Aicardi–Goutières Syndrome: an update and results of interferon-α studies. Ann. Neurology. 1998;44:900–907
  27. Hilsabeck RC, Perry W, Hassassein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440–446
  28. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J. Int. Neuropsychol. Soc. 2003;9:847–854
  29. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J. Int. Neuropsychol. Soc. 2005;11:16–22
  30. Holliday SL, Navarrete MG, Hermosillo-Romo D, Valdez CR, Saklad AR, Escalante A, et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus. 2003;12:697–703
  31. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N. Eng. J. Med. 1979;301:5–8
  32. Huckans M, Seelye A, Parcel T, Mull L, Woodhouse J, Bjornson D, et al. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. JINS. 2009;15:69–82
  33. Isshi K, Hirohata S, Hashimoto T, Miyashita H. Systemic lupus erythematosus presenting with diffuse low density lesions in the cerebral white matter on computed axial tomography scans: its implication in the pathogenesis of diffuse central nervous system lupus. J. Rheumatol. 1994;21:1758–1762
  34. Jankowsky JL, Patterson PH. Cytokine and growth factor involvement in long-term potentiation. Mol. Cell. Neurosci. 1999;14:273–286
  35. Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. Semin. Oncol. 1998;25:54–63
  36. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology. 2000;152:383–389
  37. Kamei S, Tanaka N, Mastuura M, Arakawa Y, Kojima T, Matsukawa Y, et al. Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol. Scand. 1999;100:25–33
  38. Kamei S, Sakai T, Matsuura M, Tanaka N, Kojima T, Arakawa Y, et al. Alterations of quantitative EEG and Mini-Mental State Examination in interferon-α-treated hepatitis C. Eur. Neurol. 2002;48:102–107
  39. Kamei S, Oga K, Matsuura M, Tanaka N, Kojima T, Arakawa Y, et al. Correlation between quantitative-EEG alterations and age in patients with interferon-alpha-treated hepatitis C. J. Clin. Neurophys. 2005;22:49–52
  40. Kane RL, Roebuck-Spencer T, Short P, Kabat M, Wilken J. Identifying and monitoring cognitive deficits in clinical populations using Automated Neuropsychological Assessment Metrics (ANAM) tests. Arch. Clin. Neuropsychol. 2007;22:S115–S126
  41. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J. Hepatol. 2002;37:349–354
  42. Kraus MR, Schafer A, Wissmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin. Pharmacol. Ther. 2005;77:90–100
  43. Krivine A, Force G, Servan J, Cabee A, Rozenberg F, Dighiero L, et al. Measuring HIV-1 RNA and interferon-α in the cerebrospinal fluid or AIDS patients: insights into the pathogenesis of AIDS dementia complex. J. Neurovirol. 1999;5:500–506
  44. Kronfol Z. Cytokines and Mental Health. Norwell, MA: Kluwer Academic Publishers; 2003;
  45. Lanzi G, Fazzi E, D'Arrigo S, Orcesi S, Maraucci I, Uggetti C, et al. The natural history of Aicardi–Goutieres syndrome: follow-up of 11 Italian patients. Neurology. 2005;64:1621–1624
  46. Lau AS, Der SD, Read SE, Williams BRG. Regulation of tumor necrosis factor receptor expression by acid-labile interferon-α from AIDS sera. AIDS Res. Hum. Retroviruses. 1991;7:545–552
  47. Lebon P, Lenoir GR, Fischer A, Lagrue A. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Br. Med. J. Clin. Res. Ed. 1983;287:1165–1167
  48. Lee S, Macquillan GC, Keane NM, Flexman J, Jeffrey GP, French MA, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol. Cell Biol. 2002;80:391–397
  49. Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin. Oncol. 1998;25:30–38
  50. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 2008;430:264–268
  51. Magaki S, Meuller C, Dickson C, Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 2007;42:233–240
  52. Maier SF. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav. Immun. 2003;17:69–85
  53. Majer M, Welberg LAM, Capuron L, Pagnoni G, Raison CL, Miller AH. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 2008;22:870–880
  54. Marsland AL, Petersen KL, Sathanoori R, Muldoon MF, Neumann SA, Ryan C, et al. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom. Med. 2006;68:895–903
  55. Mathur A, Choudhary HR. Systemic lupus erythematosus causing cerebral infarction and basal ganglion calcification: a case report. Neurol. India. 2000;48:91
  56. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009;33:355–366
  57. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801–808
  58. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–793
  59. Migita K, Abiru S, Maeda Y, Daikoku M, Ohata K, Nakamura M, et al. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum. Immunol. 2006;67:27–32
  60. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig. Dis. Sci. 1997;42:2487–2494
  61. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 2002;17:196–202
  62. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, et al. Cytokine–chemokine and apoptotic signatures in patients with hepatitis C. Transl. Res.: J. Lab. Clin. Med. 2007;149:126–136
  63. Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-Jablonska J. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen. Hos. Psychiatry. 2008;30:501–508
  64. Perrella O, Carrieri PB, Perrella A, Sbreglia C, Gorga F, Guarnaccia D, et al. Transforming growth factor-beta1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load?. Eur. Cytokine Network. 2001;12:51–55
  65. Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig. Dis. Sci. 2008;53:307–321
  66. Petitto JM, McNamara RK, Gendreau PL, Huang Z, Jackson AJ. Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin-2 gene deletion. J. Neurosci. Res. 1999;56:441–446
  67. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 2006;20:169–174
  68. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. App. Psychol. Measurement. 1977;1:385–401
  69. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J. Am. Ger. Soc. 2007;55:700–707
  70. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry. 2009;65:296–303
  71. Raymond AA, Zariah AA, Samad SA, Chin CN, Kong NC. Brain calcification in patients with cerebral lupus. Lupus. 1996;5:123–128
  72. Reeves D, Kane R, Winter K. ANAM V3.11a/96 user's manual: clinical and neurotoxicology subsets. San Diego, CA: National Cognitive Recovery Foundation; 1996;
  73. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psych. 2001;58:445–452
  74. Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Criffin J, et al. A potential role for interferon-α in the pathogenesis of HIV-associated dementia. Brain Behav. Immun. 1995;9:366–377
  75. Roebuck-Spencer TM, Reeves DL, Bleiberg J, Cernich AN, Schwab K, Ivins B, et al. Influence of demographics on computerized cognitive testing in a military sample. Mil. Psychol. 2009;20:1–17
  76. Rönnblom L, Alm GV. A pivotal role for the natural interferon-α producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 2001;194:F59–F63
  77. Sarder M, Abe K, Saito H, Nishiyama N. Comparative effect of IL-2 and IL-6 on morphology of cultured hippocampal neurons from fetal rat brain. Brain Res. 1996;715:9–16
  78. Schram MT, Euser SM, de Craen AJ, Witteman JC, Frolich M, Hofman A, et al. Systemic markers of inflammation and cognitive decline in old age. J. Am. Ger. Soc. 2007;55:708–716
  79. Schultz M, Muller R, von zur Muhlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet. 1989;1:1452
  80. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59:S22–S33
  81. Shimizu H, Ohtani KI, Sato N, Nagamine T, Mori M. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-α administration. Endocr. J. 1995;42:551–556
  82. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992;35:417–422
  83. Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, Klimas N. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup?. J. Psychosom. Res. 2006;60:559–566
  84. Verma V, Chakravarti A, Kar P. Cytokine levels of TGF-beta, IL-10, and sTNFalphaRII in type C chronic liver disease. Dig. Dis. Sci. 2008;53:2233–2237
  85. Vial T, Choquet-Kastylevsky G, Liautard C, Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology. 2000;142:161–172
  86. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371–378
  87. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, et al. Hepatitis C virus infection affects the brain—evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol. 2004;41:845–851
  88. Wilken JA, Sullivan CL, Lewandowski A, Kane RL. The use of ANAM to assess the side-effect profiles and efficacy of medication. Arch. Clin. Neuropsychol. 2007;22:S127–S133
  89. Wilson CJ, Cohen HJ, Pieper CF. Cross-linked fibrin degradation products (D-Dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J. Am. Ger. Soc. 2003;51:1374–1381
  90. Wright H, Alex P, Nguyen T, Bader T, Gurakar A, Sebastian A, et al. Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. Dig. Dis. Sci. 2005;50:1793–1803
  91. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune system. J. Neuroimmunol. 2006;172:38–58
  92. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76–80
  93. Yamada T, Yamanaka I. Microglial localization of α-interferon receptor in human brain tissues. Neurosci. Lett. 1995;189:73–76
  94. Yamada T, Horisberger MA, Kawaguchi N, Moroo I, Toydoa T. Immunohistochemistry using antibodies to α-interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci. Lett. 1994;181:61–64

PII: S0165-5728(10)00038-X

doi: 10.1016/j.jneuroim.2010.01.017

Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 53-61 , 15 April 2010

Article Tools